POINT Biopharma Global Inc. (PNT) financial statements (2022 and earlier)

Company profile

Business Address 4850 WEST 78TH STREET
INDIANAPOLIS, IN 46268
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments238,816252,826273,7377001,0951,14165
Cash and cash equivalents238,816252,826273,7377001,0951,14165
Prepaid expense2,1753,1043,98089106124 
Other current assets10517365    
Other undisclosed current assets2,7503,1914,027(0)   
Total current assets:243,847259,294281,8087881,2011,26565
Noncurrent Assets
Property, plant and equipment19,41217,90215,654    
Assets held-in-trust   135,710135,706135,703 
Deferred costs      449
Total noncurrent assets:19,41217,90215,654135,710135,706135,703449
TOTAL ASSETS:263,259277,196297,463136,498136,907136,968514
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,9808,0948,3531,10811852234
Accounts payable1,7383,2185,018353556
Accrued liabilities5,9914,6743,14675511347227
Taxes payable251202189    
Debt  3,556    
Due to related parties      275
Other undisclosed current liabilities   4,750   
Total current liabilities:7,9808,09411,9105,85711852509
Noncurrent Liabilities
Liabilities, other than long-term debt666363    
Deferred income tax liabilities666363    
Other undisclosed noncurrent liabilities    4,7504,750 
Total noncurrent liabilities:666363 4,7504,750 
Total liabilities:8,0468,15711,9725,8574,8674,801509
Temporary equity, carrying amount   125,641127,040127,167 
Stockholders' equity
Stockholders' equity attributable to parent, including:255,213269,039285,4905,0005,0005,0006
Common stock999    
Additional paid in capital314,489314,118313,4536,7105,3115,18425
Accumulated deficit(59,285)(45,088)(27,971)(1,711)(312)(185)(19)
Other undisclosed stockholders' equity attributable to parent   0000
Total stockholders' equity:255,213269,039285,4905,0005,0005,0006
TOTAL LIABILITIES AND EQUITY:263,259277,196297,463136,498136,907136,968514

Income statement (P&L) ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Operating expenses(14,096)(17,031)(8,650)    
Other undisclosed operating loss   (1,402) (168) 
Operating loss:(14,096)(17,031)(8,650)(1,402) (168) 
Nonoperating income (expense)(40)(4)(30)3 3 
Investment income, nonoperating   3 3 
Other nonoperating expense(40)(4)(30)    
Loss from continuing operations before income taxes:(14,136)(17,036)(8,681)(1,399) (165) 
Income tax expense(60)(81)(124)    
Loss before gain (loss) on sale of properties:(14,197)(17,117)(8,805)(1,399) (165) 
Other undisclosed net loss      (19)
Net loss available to common stockholders, diluted:(14,197)(17,117)(8,805)(1,399) (165)(19)

Comprehensive Income ($ in thousands)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net loss:(14,197)(17,117)(8,805)(1,399) (165)(19)
Comprehensive loss, net of tax, attributable to parent:(14,197)(17,117)(8,805)(1,399) (165)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: